101 related articles for article (PubMed ID: 34069373)
1. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
Son Y; Shin NR; Kim SH; Park SC; Lee HJ
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373
[TBL] [Abstract][Full Text] [Related]
2. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
[TBL] [Abstract][Full Text] [Related]
3. Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death.
Xie L; Zeng Y; Dai Z; He W; Ke H; Lin Q; Chen Y; Bu J; Lin D; Zheng M
Int J Biol Sci; 2018; 14(5):577-585. PubMed ID: 29805309
[TBL] [Abstract][Full Text] [Related]
4. Role of Fibrinogen-like Protein 1 in Tumor Recurrence Following Hepatectomy.
Shafieizadeh Z; Shafieizadeh Z; Davoudi M; Afrisham R; Miao X
J Clin Transl Hepatol; 2024 Apr; 12(4):406-415. PubMed ID: 38638375
[TBL] [Abstract][Full Text] [Related]
5. FGL1 and FGL2: emerging regulators of liver health and disease.
Chen J; Wu L; Li Y
Biomark Res; 2024 May; 12(1):53. PubMed ID: 38816776
[TBL] [Abstract][Full Text] [Related]
6. FAT10 mediates the sorafenib-resistance of hepatocellular carcinoma cells by stabilizing E3 ligase NEDD4 to enhance PTEN/AKT pathway-induced autophagy.
Zhang W; Du D; Lu H; Zhang D; Liu L; Li J; Chen Z; Yu X; Ye M; Wang W; Chen L; Shao J
Am J Cancer Res; 2024; 14(4):1523-1544. PubMed ID: 38726263
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Sorafenib Resistance in HCC Culture Relate to the Impaired Membrane Expression of Organic Cation Transporter 1 (OCT1).
Chava S; Ekmen N; Ferraris P; Aydin Y; Moroz K; Wu T; Thung SN; Dash S
J Hepatocell Carcinoma; 2024; 11():839-855. PubMed ID: 38741679
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells.
Rodrigo MAM; Michalkova H; Jimenez AMJ; Petrlak F; Do T; Sivak L; Haddad Y; Kubickova P; de Los Rios V; Casal JI; Serrano-Macia M; Delgado TC; Boix L; Bruix J; Martinez Chantar ML; Adam V; Heger Z
Biomark Res; 2024 Apr; 12(1):38. PubMed ID: 38594765
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative Activity of
Andrade AAR; Pauli F; Pressete CG; Zavan B; Hanemann JAC; Miyazawa M; Fonseca R; Caixeta ES; Nacif JLM; Aissa AF; Barreiro EJ; Ionta M
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672246
[TBL] [Abstract][Full Text] [Related]
10. Profiling the circulating mRNA transcriptome in human liver disease.
Sayeed A; Dalvano BE; Kaplan DE; Viswanathan U; Kulp J; Janneh AH; Hwang LY; Ertel A; Doria C; Block T
Oncotarget; 2020 Jun; 11(23):2216-2232. PubMed ID: 32577166
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W; Zhao M; Wang R; Li H
J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
[TBL] [Abstract][Full Text] [Related]
12. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
13. PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells.
Lin JC; Yang PM; Liu TP
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072570
[TBL] [Abstract][Full Text] [Related]
14. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma.
Lin M; He J; Zhang X; Sun X; Dong W; Zhang R; Xu Y; Lv L
J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115693
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.
Yang C; Qian Q; Zhao Y; Huang B; Chen R; Gong Q; Ji H; Wang C; Xia L; You Z; Zhang J; Chen X
Front Immunol; 2023; 14():1112672. PubMed ID: 36993960
[TBL] [Abstract][Full Text] [Related]
16. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma.
Hua N; Chen A; Yang C; Dong H; He X; Ru G; Tong X; Zhou F; Wang S
Mol Biol Rep; 2022 Aug; 49(8):7911-7919. PubMed ID: 35776395
[TBL] [Abstract][Full Text] [Related]
17. Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection.
Tsai HI; Wu Y; Liu X; Xu Z; Liu L; Wang C; Zhang H; Huang Y; Wang L; Zhang W; Su D; Khan FU; Zhu X; Yang R; Pang Y; Eriksson JE; Zhu H; Wang D; Jia B; Cheng F; Chen H
Adv Sci (Weinh); 2022 Jan; 9(3):e2102634. PubMed ID: 34738731
[TBL] [Abstract][Full Text] [Related]
18. Proteomics identifies a novel role of fibrinogen-like protein 1 in Crohn's disease.
Sun XL; Qiao LC; Gong J; Wen K; Xu ZZ; Yang BL
World J Gastroenterol; 2021 Sep; 27(35):5946-5957. PubMed ID: 34629811
[TBL] [Abstract][Full Text] [Related]
19. Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma.
Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
Comput Struct Biotechnol J; 2021; 19():2775-2789. PubMed ID: 34093992
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases.
Zhu Y; Xu J; Hu W; Wang F; Zhou Y; Gong W; Xu W
Aging (Albany NY); 2021 Jun; 13(11):14999-15012. PubMed ID: 34081623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
